Detection of Malignant Tumors by Nuclear Magnetic Resonance Spectroscopy of Plasma

Fritz F. Parl, Thomas M. Harris, Brian D. Ross, Peter B. Barker, Crispin G.s. Eley, Paul G. Schmidt, John D. Roberts, Mark C. Regan, Charles Cottrell, Donald M. Small, James A. Hamilton, Robert A. Campbell, Wim J. Van Blitterswijk, Carolyn E. Mountford, Eric T. Fossel, Justine M. Carr, Jan McDonagh

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: We were intrigued by the study of Fossel et al. (Nov. 27 issue)1 and the claim that water-suppressed proton nuclear magnetic resonance (NMR) spectroscopy of plasma may be useful for the detection of malignant tumors. We have compared proton NMR spectroscopy with the measurement of two tumor markers of proved value in the detection and monitoring of patients with cancer — carcinoembryonic antigen and alpha-fetoprotein.2 We obtained serum from 20 patients who had elevated levels of carcinoembryonic antigen or alpha-fetoprotein and were given a diagnosis of malignant tumors. A group of 20 patients without clinical evidence of.

Original languageEnglish (US)
Pages (from-to)1411-1415
Number of pages5
JournalNew England Journal of Medicine
Volume316
Issue number22
DOIs
StatePublished - May 28 1987
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Detection of Malignant Tumors by Nuclear Magnetic Resonance Spectroscopy of Plasma'. Together they form a unique fingerprint.

Cite this